anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

172,321-172,380 of 319,975

filter-aware
01
Slide 1
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Situation & Context1 hit
02
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Situation & Context1 hit
03
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Situation & Context1 hit
04
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Situation & Context1 hit
05
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
06
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
07
The slide uses a bar chart to compare 23andMe's 11.9M participants against other biobanks and research programs.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
08
The slide uses a circular process flow to represent a self-reinforcing business model.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
09
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
10
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
11
The slide uses a split-screen layout with a blue background on the left for the thesis and a white background on the right for supporting metrics.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
12
The slide uses a contrast-pairs framework to show the advantage of genetic evidence in drug development.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
13
Uses a process flow diagram to explain the company's core R&D methodology.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
14
The slide highlights the scale of the 23andMe database for medical research.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
15
The slide uses a timeline-style layout to show drug development progress.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
16
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
17
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
18
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
19
Uses a 'bench to bedside' bidirectional flow model to explain drug development strategy.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
20
The slide uses a funnel metaphor to show the narrowing of research focus from broad data to specific drug targets.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Solution & Approach1 hit
21
The slide uses a heatmap-style visualization to show opposing effects of genes on immune vs cancer phenotypes.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
22
Includes an immunohistochemistry image showing CD200 expression and a schematic diagram of the antibody mechanism.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a circular flow diagram to represent a business flywheel model.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
24
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
25
Includes a Manhattan plot and a zoomed-in regional association plot.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
26
The slide uses Manhattan plots to show the density of genetic associations increasing over time, paired with a line chart showing the cumulative growth of independent hits.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
27
Uses a 'fill in the blanks' analogy to explain a technical process.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
28
Includes a visual process diagram of imputation and a before/after Manhattan plot comparison.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
29
The slide uses a Venn diagram to illustrate the overlap between two gene discovery methods.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
30
The slide uses a grid of small heatmaps/bar charts to visualize data across 10 medical categories. A specific example for NAFLD is highlighted at the bottom.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Beat · Evidence & Proof1 hit
31
The heatmap shows statistical significance of associations with O blood type, with red indicating increased risk and blue indicating decreased risk.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
32
The slide illustrates a PheWAS (Phenome-wide association study) approach using a similarity classifier to identify genes matching a known CTLA4 immuno-oncology signature.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
33
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
34
The slide uses a three-part flow: market size (left), industry landscape (center), and 23andMe's proprietary identification method (right).23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
35
The slide uses heatmaps to visualize genetic associations with various phenotypes, highlighting the CD200R1 pathway.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
36
The slide uses a biological pathway diagram to illustrate the mechanism of action.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
37
The slide uses a before-after visual to illustrate the mechanism of action.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
38
The slide uses a bar chart to demonstrate efficacy across 9 different patient samples (Endometrial, Ovarian, Lung, Melanoma, Pancreatic, Prostate, Colorectal).23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
39
Clinical trial design schematic showing patient population, study parts (A and B), and primary/secondary objectives.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
40
The slide uses visual evidence (microscopy) to support the thesis of co-expression.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
41
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
42
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
43
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
44
The slide uses heatmaps to show genetic associations (signed log(p)) for CTLA4 and CD96/CD226 pathways.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
45
The slide uses a biological interaction map to explain the rationale for combination therapy.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
46
The chart shows tumor volume over time for various monotherapy and combination therapy groups, highlighting the triple combination's efficacy.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
47
Includes a process flow diagram for study arms and a table for endpoints.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
48
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
49
23andMe | Investor Day Presentation Deck | 78 slides23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
50
The slide uses a large circular graphic to focus attention on the central question.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
51
The slide outlines the 23andMe pipeline from sample collection to FDA-authorized reporting.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
52
The slide presents a collection of survival curves and hazard ratio plots from various clinical trials and academic publications.23andMe | Investor Day Presentation Deck | 78 slides · 23andMe
Conference presentation Investor relations 1 hit
17
WPP | Investor Day Presentation Deck | 24 slidesWPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
18
The slide uses a wave-like background to represent the journey flow, with circular nodes representing specific technology domains.WPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
19
The slide uses a process-oriented layout to categorize various marketing and commerce technology tools.WPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
20
The slide uses a complex grid-based taxonomy to categorize business capabilities. It is a high-level architectural map of enterprise marketing and commerce technology.WPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
21
WPP | Investor Day Presentation Deck | 24 slidesWPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
22
The slide functions as a portfolio or track record of thought leadership publications.WPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
23
WPP | Investor Day Presentation Deck | 24 slidesWPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit
24
WPP | Investor Day Presentation Deck | 24 slidesWPP | Investor Day Presentation Deck | 24 slides · Wunderman Thompson
Conference presentation Investor relations 1 hit